Key Highlights

• Investors have two mainboard IPOs to choose from this week as Dhoot Transmission and Molbio Diagnostics open for subscription on August 10.
• Dhoot Transmission is currently leading in grey market sentiment with a significantly higher Grey Market Premium (GMP).
• Molbio Diagnostics continues to attract attention from long-term investors due to its presence in the molecular diagnostics and healthcare technology sector.
• Dhoot Transmission operates in the automotive electrical systems segment, supplying wiring harnesses, battery packs and EV components.
• Molbio Diagnostics develops rapid molecular diagnostic solutions through its Truenat platform for diseases including TB, HIV, COVID-19 and Hepatitis.
• Both IPOs are considered reasonably valued when compared with listed peers in their respective industries.
• Dhoot's financial performance, EV market leadership and stable GMP make it a preferred choice for listing gains.
• Molbio Diagnostics remains a potential long-term investment for investors seeking exposure to India's growing healthcare diagnostics market.
• Both companies have sector-specific risks that investors should evaluate before applying.
• Investment decisions should be based on financial goals, risk appetite and company fundamentals rather than GMP alone.

With two major IPOs opening for subscription this week, investors are comparing Dhoot Transmission and Molbio Diagnostics to identify which issue offers stronger listing gains and long-term growth potential. While both companies belong to completely different industries, they have attracted considerable interest from the primary market.

Dhoot Transmission enjoys stronger grey market sentiment

Current grey market trends indicate stronger demand for Dhoot Transmission. The IPO is commanding a premium of around Rs 259, suggesting potential listing gains close to 30% over its upper issue price.

Market observers also note that the GMP has remained relatively stable over the past week, reflecting sustained investor confidence ahead of listing.

Molbio Diagnostics, on the other hand, is witnessing a GMP of around Rs 122, implying expected listing gains of approximately 15%. Although still positive, the premium has moderated compared to earlier levels.

It is important to remember that GMP is an unofficial market indicator and should not be treated as a guarantee of listing performance.

Financial performance comparison

Dhoot Transmission enters the IPO market as the larger company in terms of revenue and profitability.

The company reported:

• Revenue of Rs 4,524.9 crore in FY26
• Net profit of Rs 396.8 crore
• Three-year revenue CAGR of approximately 27%

Molbio Diagnostics reported:

• Revenue of Rs 1,445.6 crore
• Net profit of Rs 164.1 crore

Although smaller in scale, Molbio has demonstrated consistent growth in both revenue and earnings over recent years.

Business strengths

Dhoot Transmission

Dhoot manufactures:

• Wiring harnesses
• Battery packs
• Sensors
• Connectors
• Electrical distribution systems

The company holds a strong position in India's electric two-wheeler and three-wheeler market and continues expanding manufacturing capacity to meet increasing EV demand.

Molbio Diagnostics

Molbio focuses on rapid molecular diagnostics through its Truenat platform, offering portable PCR-based testing solutions.

Its products are widely used for diagnosing:

• Tuberculosis
• COVID-19
• HIV
• Hepatitis
• HPV

The company also has a growing presence in government healthcare programmes and international markets.

Valuation comparison

Both IPOs appear reasonably priced relative to their listed peers.

• Dhoot Transmission is valued at approximately 41.4x earnings, comparable to major auto component companies.
• Molbio Diagnostics is valued at around 55.4x earnings, broadly in line with established diagnostic companies.

Neither issue appears excessively expensive based on industry standards.

Risks investors should consider

Dhoot Transmission

Potential risks include:

• Dependence on a limited number of large customers
• Exposure to fluctuations in raw material prices
• Cyclical demand in the automobile industry

Molbio Diagnostics

Key risks include:

• Dependence on government procurement
• Revenue concentration in tuberculosis diagnostics
• Regulatory approval delays for new diagnostic products

Which IPO looks better?

For investors seeking short-term listing gains, Dhoot Transmission currently appears to have the advantage due to its stronger grey market premium, larger business scale, robust financial growth and leadership in the fast-growing EV component segment.

Molbio Diagnostics, however, remains a compelling option for long-term investors who want exposure to India's expanding healthcare diagnostics industry and innovative molecular testing technology.

Ultimately, investors should assess business fundamentals, valuation and risk factors before making any investment decision.

Frequently Asked Questions (FAQs)

1. Which IPO opens for subscription on August 10?

Both Dhoot Transmission and Molbio Diagnostics open for subscription on August 10.

2. Which IPO has the higher Grey Market Premium?

Dhoot Transmission currently has a higher GMP than Molbio Diagnostics.

3. Is Grey Market Premium a reliable indicator?

No. GMP reflects market sentiment but does not guarantee listing performance.

4. What does Dhoot Transmission manufacture?

The company manufactures wiring harnesses, battery packs, sensors, connectors and electrical systems for the automotive industry.

5. What is Molbio Diagnostics known for?

Molbio develops rapid molecular diagnostic solutions using its Truenat platform.

6. Which IPO appears better for listing gains?

Based on current GMP trends and financials, Dhoot Transmission appears better positioned for listing gains.

7. Which IPO may suit long-term investors?

Molbio Diagnostics may appeal to long-term investors interested in healthcare and diagnostics.

8. What are the biggest risks for Dhoot Transmission?

Customer concentration, raw material costs and dependence on automobile demand.

9. What are the major risks for Molbio Diagnostics?

Government procurement dependence, regulatory approvals and product concentration.

10. Should investors rely only on GMP before investing?

No. Investors should evaluate company fundamentals, financials, valuation and business prospects along with market sentiment.